Blazing Star Merger Sub completes Walgreens debt tender offer
Investing.com - Processa Pharmaceuticals reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Processa Pharmaceuticals announced earnings per share of $-0.370 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.298 on revenue of $0.00.
Processa Pharmaceuticals 's are down 48.09% and is trading at $2.150 , still down 69.85% from its 52 week high of $7.13 set on Thursday, November 11, 2021.
Processa Pharmaceuticals follows other major Healthcare sector earnings this month
Processa Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar